Skip to main navigation

Sagimet Biosciences

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

News Releases

Year

9/30/2026

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

9/30/2026

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

9/28/2026

Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026

9/2/2026

Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences

8/25/2026

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

8/17/2026

Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

8/13/2026

Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

8/11/2026

Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

8/4/2026

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

6/29/2026

Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Site Map

About
Science
Investors
Programs
Contact

Contact Us

Business Development:
bd@sagimet.com

Investors:
ir@sagimet.com

Media:
media@sagimet.com

© 2026 Sagimet Biosciences Inc.. All Rights Reserved.

Close line1 Close line2

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact